Physician profile
Chris Grevengood
NPI 1225087273
$549.56
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $138 · 2021: $91.88 · 2022: $97.87.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $272.30 | 2019-2021 | |
| Intuitive Surgical, INC. | $49.25 | 2019 | |
| Exeltis, USA INC. | $46.19 | 2021-2022 | |
| Arthrex, INC. | $45.00 | 2019 | |
| Amarin Pharma, INC. | $43.82 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.95 | 2022 | |
| Merck Sharp & Dohme LLC | $17.43 | 2022 | |
| Medicem INC. | $16.21 | 2022 | |
| Almatica Pharma LLC | $13.86 | 2022 | |
| Mylan Pharmaceuticals INC. | $12.94 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.61 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Grevengood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.